Newsroom

May 19, 2021-The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time

May 18, 2021-Data presented at the ISPOR 2021 Conference illustrating clinical benefit as well as cost savings

April 28, 2021-Several prominent healthcare-focused institutional investors fund Sera to expand commercialization of the PreTRM® Test.

April 13, 2021-Highly accomplished attorney joins Sera to develop its legal and intellectual property functions.

March 31, 2021- Accomplished technology leader joins Sera to build and deploy its information strategy.

February 3, 2021- Receipt of dedicated CPT® code marks important commercialization milestone to pursue reimbursement for the PreTRM® Test.

January 05, 2021- Patient enrollment began in November for this rigorous prospective, randomized, controlled PRIME intervention trial to demonstrate the value of implementing the PreTRM® prevention strategy to improve neonatal outcomes and lower cost of care.

September 9, 2020- Sera will be presenting at the upcoming Baird 2020 Global Health Care Conference. A virtual conference, Sera’s presentation will take place on Thursday, September 10 at 10:50 a.m. ET.

June 24, 2020 – Sera announced the appointment Thomas J. Garite, M.D. as Vice President of Clinical Sciences. – Dr. Garite will support clinical development and operations as Sera transitions from clinical to commercial-stage company.

May 20, 2020 – Sera, Inc., The Pregnancy Company® announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal Medicine.